Literature DB >> 15582655

Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.

Gene S Tan1, Philip M McKenna, Martin L Koser, Robert McLinden, Jerome H Kim, James P McGettigan, Matthias J Schnell.   

Abstract

Recombinant rhabdovirus vectors expressing human immunodeficiency virus (HIV) and/or simian immunodeficiency virus (SIV) proteins have been shown to induce strong immune responses in mice and rhesus macaques. However, the finding that such responses protect rhesus macaques from AIDS-like disease but not from infection indicates that further improvements for these vectors are needed. Here, we designed a prime-boost schedule consisting of a rabies virus (RV) vaccine strain and a recombinant vesicular stomatitis virus (VSV) both expressing HIV Envelope (Env). Mice were primed and boosted with the two vaccine vehicles by different routes and in different combinations. Mucosal and systemic humoral responses were assessed using enzyme linked immunosorbent assay (ELISA) while the cellular immune response was determined by an IFN-gamma ELISPOT assay. We found that an immunization combination of RV and VSV elicited the highest titers of anti-Env antibodies and the greatest amount of Env-specific IFN-gamma secreting cells pre- and post-challenge with a recombinant vaccinia virus expressing HIV(89.6) Env. Furthermore, intramuscular immunization did not induce antigen-specific mucosal antibodies while intranasal inoculation stimulated vector-specific IgA antibodies in vaginal washings and serum. Our results show that it is feasible to elicit robust cellular and humoral anti-HIV responses using two different live attenuated Rhabdovirus vectors to sequentially prime and boost.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15582655     DOI: 10.1016/j.virol.2004.10.018

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  23 in total

1.  Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.

Authors:  Celestine N Wanjalla; Elizabeth J Faul; Emily A Gomme; Matthias J Schnell
Journal:  Vaccine       Date:  2010-08-20       Impact factor: 3.641

2.  Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.

Authors:  William A Langley; Konrad C Bradley; Zhu-Nan Li; Mary Ellen Smith; Matthias J Schnell; David A Steinhauer
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

Review 3.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

4.  Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Authors:  John B Schell; Nina F Rose; Kapil Bahl; Kathryn Diller; Linda Buonocore; Meredith Hunter; Preston A Marx; Ratish Gambhira; Haili Tang; David C Montefiori; Welkin E Johnson; John K Rose
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

Review 5.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

6.  PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity.

Authors:  Christoph Wirblich; Gene S Tan; Amy Papaneri; Peter J Godlewski; Jan Marc Orenstein; Ronald N Harty; Matthias J Schnell
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

7.  Characterization of a single-cycle rabies virus-based vaccine vector.

Authors:  Emily A Gomme; Elizabeth J Faul; Phyllis Flomenberg; James P McGettigan; Matthias J Schnell
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

8.  Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector.

Authors:  Yuanmei Ma; Yue Duan; Yongwei Wei; Xueya Liang; Stefan Niewiesk; Michael Oglesbee; Jianrong Li
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

9.  Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.

Authors:  Janet L Brandsma; Mark Shlyankevich; Yuhua Su; Daniel Zelterman; John K Rose; Linda Buonocore
Journal:  Vaccine       Date:  2009-07-15       Impact factor: 3.641

10.  Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.

Authors:  Adam E Snook; Benjamin J Stafford; Peng Li; Gene Tan; Lan Huang; Ruth Birbe; Stephanie Schulz; Matthias J Schnell; Mathew Thakur; Jay L Rothstein; Laurence C Eisenlohr; Scott A Waldman
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.